secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2023-12-12T23:59:59+00:00
Accession:  0000950170-23-069533
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants Fast Track Designation to Candel's CAN-2409 for pancreatic cancer
----------------------------------------------------------------------------

- FDA Fast Track Designation for CAN-2409 (adenovirus immunotherapy) plus valacyclovir in pancreatic ductal adenocarcinoma (PDAC) to improve overall survival.
- Phase 2 interim data (Nov 2023): 71.4% estimated survival at 24 and 36 months with CAN-2409 + SoC vs 16.7% for SoC alone in borderline resectable PDAC.
- Updated overall survival data from interim analysis expected Q2 2024.
- CAN-2409 shown to activate immunologic antitumoral response in 'cold' tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017023069533/0000950170-23-069533-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017023069533/cadl-20231212.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-069533

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer